Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
News
Market Highlights: ASX to test new record in a high-stakes week; and 5 small caps to watch
News
ASX Rebalance: Copper in, lithium out as hot biotechs climb ranks
Health & Biotech
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
Health & Biotech
ASX Health Stocks: Inoviq’s tech boosts early detection of Parkinson’s disease
News
Market Highlights: Wall Street rallies hard after inflation data; Starbucks steals Chipotle’s CEO
Health & Biotech
ASX Health Stocks: Immutep gets positive FDA feedback for lung cancer therapy
News
Market Highlights: CrowdStrike plunges 11pc after global outage, as Biden pulls out of race
Health & Biotech
ASX Health Stocks: Immutep gets crucial therapy trial clearance; Alcidion wins $4m deal
News
Top 10 at 11: A positive drug trial and investor webinars are making news today
Health & Biotech
ScoPo’s Powerplays: ASX health stocks end the week ahead despite freaky inflation data
News
Closing Bell: Abominable inflation has ASX in full retreat
Health & Biotech
ASX Health Stocks: Immutep sinks 35pc despite positive results from cancer-treatment trial
News
Market Highlights: Amazon hits US$2T cap for first time, and property market to remain strong next year
News
Closing Bell: The good news is the ASX is higher. The better news is the economy’s shot
Health & Biotech
Immutep’s clinical trials are advancing rapidly; here are the next catalysts for investors
Health & Biotech
ASX Health Stocks: Immutep shares exciting early results from Phase 2 trial on soft tissue sarcoma
News
